This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merck KGaA, Oncothyreon Lung Cancer Drug Fails Late-Stage Study

Stocks in this article: ONTY DNDN

Updated with Wednesday's stock price

DARMSTADT, Germany ( TheStreet) -- Stimuvax, an experimental cancer immunotherapy from Merck KGaA and Oncothyreon (ONTY), failed to improve survival in a late-stage study of non-small cell lung cancer patients, the companies announced Wednesday.

Detailed results from the Stimuvax phase III lung cancer study were not disclosed, except "notable treatment effects" were seen in certain subgroups of lung cancer patients treated with the drug, Merck said.

The negative study result is a significant setback for Merck, which was counting on Stimuvax to resurrect a drug development program that's seen better days. Stimuvax was also the most important drug in Oncothyreon's research pipeline, which will now be headlined by PX-866, a PI-13 kinase inhibitor in mid-stage studies.

Oncothyreon shares closed Tuesday at $4.49, ahead of the negative Stimuvax news. The stock was down 57.7% in trading Wednesday to $1.91.

Stimuvax was designed to train a patient's immune system to recognize a protein known as MUC1, which is over-expressed in a number of different cancers, including non-small cell lung cancer. This is a similar approach to that taken by Dendreon (DNDN) with the prostate cancer immunotherapy Provenge.

The phase III study enrolled 1,500 patients with non-small cell lung cancer, randomized to treatment with Stimuvax (also known as L-BLP25) or a placebo. The study's primary endpoint, an improvement in overall survival, was not met.

An interim analysis of the study was previously performed last March, demonstrating no significant survival benefit for Stimuvax-treated patients. The study was allowed to continue, however, even though odds of a successful outcome were diminished drastically.

The rationale for the phase III Stimuvax lung cancer trial was always sketchy, coming from a retrospective subset analysis of a phase II trial.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs